SANEMUS supports a telemedicine start-up in fundraising. The start-up has developed a telemedicine system for the adjustment of medication of Parkinson’s Disease patients at home. After a successful test phase in inpatient and outpatient care, the market launch of the system in Germany is scheduled for autumn 2018. First talks with potential investors are being held. If you are interested in participating, please contact us.

SANEMUS has a new board of directors. Chairman is Dr. Theo Trucksaess assisted by Dr. Dr. Michael Dahm and Bernd Seibel. 

Dr. Theo Trucksaess is European Partner of Shentou Investment Co. Ltd. Dr. Dr. Michael Dahm is CMO of ORYX GmbH & Co. KG. Bernd Seibel, former General Partner at TVM, is investing as Business Angel in different Life Science companies.

The SANEMUS team welcomes the new members of the board of directors and is looking forward to the cooperation!

In the cover story of the latest issue of Life Sciences Platform, “Biotechnology 2017”, Dr. Thiel gives an overview of the development of the life science industry in the current year.

Many doubts were raised trough electioneering in the US in 2016,  but meanwhile the optimism in the growth of the life science market is back. Amongst other things, the end of the discussion about a regulation of drug pricing in the US and the abandon of plans for a health care and corporate tax reform, resulted in positive impulses at the stock exchange.

You can read the whole article here→  (German-language link)

 

SANEMUS is supporting a diagnostics start-up focused on the identification and characterization of circulating tumor cells (CTC) in finding new investors. The start-up has developed a patent-protected innovative diagnostic system, which is able to identify all CTCs with higher sensitivity and specificity and faster throughput compared to current systems on the market. The address of first VCs  has occured, talks with interested parties are on-going to close the Series A in Q1/Q2 2018. If you are interested in participating, please contact us. 

The SANEMUS team supervises a biotech start-up in attracting venture capital, which has developed a proprietary technology platform for the encapsulation of nucleid acids (siRNA, mRNA) as well as low molecular compounds. The goal is the development of new RNA drugs in cancer therapy and the therapy of genetic defects. Talks are currently taking place with institutional VCs. The goal ist the closing of Series A round in Q1/Q2 2018. If you are interested in participating, please contact us. 

A German family office in the field of plant manufacturing has again invested tens of millions in an European Life Science VC fund on the recommendation of SANEMUS AG. At that time, SANEMUS prepared an overview of the healthcare market with its investment opportunities for the family office, which was the basis for the investment decision of the family office. If you are interested in participating in a Life Science VC fund, please contact us. 

Dr. Thiel, Partner at Sanemus AG, gave a lecture at the University of Maastricht, Management School, on May 8th, 2017. In his lecture, his main topic was the question: “Which sort of qualification is needed to succesfully establish a start-up?”

If you want to know more about the presentation of Dr. Michael Thiel and if you want to find out how to really achieve succes with a start-up, please do not hesitate to contact us.

In his article “Life Sciences Venture Capital-funds on the rise” in the april issue of VentureCapital magazine, Dr. Thiel reports about the success of European Life Sciences Venture Capital funds in 2016. Many large funds, such as the Endeavour Vision III-fund and Life Science Partners V-fund raised more than 200 mio. euros. Particulary pleasing from a German point of view was the first closing of the Earlybird HealthTech fund, as the public German health insurer Barmer GEK is represented here as an investor for the first time.

You can read the whole article here→ (German-language link)

Exact Imaging Inc. (Toronto), a Canadian Medtech Start-Up, successfully closed its Series C Financing Round on December 22nd 2016 at the amount of CAD 21.5 Mio. (15.4 Mio. €). SANEMUS AG was in charge of finding the European investors.

Please find more information in the press release

 

The SANEMUS team supports a second Canadian medtech Start-Up for raising venture capital. The Start-Up has developed a non-invasive device to prevent reperfusion injuries caused by ischemia. The team is currently actively searching co-investors in Europe.